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PRM243
REPRESENTiNg THE THRESHOlD iN THE COST-EffECTivENESS PlANE: 
PROPOSiNg A NEw gRAPHiCAl CONvENTiON
O’Mahony JF
Trinity College Dublin, Dublin, Ireland
BAckground: The aim of this presentation is to explain why the standard cost-
effectiveness (CE) plane gives an incomplete representation of the cost-effective-
ness of intervention strategies and to show how this problem is easily solved. The 
CE plane is the standard graphical framework for presenting costs, effects and 
incremental cost-effectiveness ratios (ICERs) of alternative intervention strategies. 
Comparing multiple strategies typically yields an increasingly steep efficient fron-
tier, indicating that strategies become progressively less cost-effective as the ICER 
rises. However, standard CE planes generally do not include the cost-effectiveness 
threshold, therefore the figure itself does not identify which strategies are cost-
effective. Consequently, the CE plane does not make it clear what strategy is optimal 
and the relative scale of costs and effects in the figure is uninformative. AnALYSIS: 
A new graphical convention is proposed whereby a line with slope equal to the cost-
effectiveness threshold is added to the CE plane. While previous examples of CE 
planes have included such threshold lines, these have drawn the threshold from the 
origin, often at 45 degrees. Using published cost-effectiveness estimates from the 
literature, we show why this approach can be problematic: it does not readily iden-
tify the optimal strategy; can confuse average and incremental cost-effectiveness 
ratios; and, can impose a scale on the diagram that obscures relevant detail. Using 
the same published examples we then demonstrate the proposed alternative of 
including a threshold line which is set tangential to the frontier rather than passing 
through the origin and is not necessarily drawn at 45 degrees. This unambiguously 
identifies the optimal strategy and provides a useful scale that graphically illustrates 
which interventions are cost-effective. concLuSIon: The simple inclusion of the 
threshold avoids several problems with the CE plane. It enhances the usefulness of 
the figure and better communicates which strategies are relevant and which are not.
PRM244
MODElliNg HEAlTH BENEfiTS ASSOCiATED TO EARly DiAgNOSiS AND 
TREATMENT Of COPD
Fiorentino F1, Alarcão J1, Bárbara C2, Costa J3, Borges M3, Gouveia M4
1Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 
2Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 3Institute of Molecular Medicine, Lisbon, 
Portugal, 4Católica Lisbon School of Business and Economics, Lisbon, Portugal
BAckground: Chronic Obstructive Pulmonary Disease (COPD) is the third main 
cause of death worldwide (WHO, 2014). For 2013, in Portugal 2,720 deaths were 
associated to COPD. Smoking is the main risk-factor and smoking cessation is 
the most effective strategy to slowdown the progression of COPD. oBjectIve: To 
model the health benefits associated to early diagnosis and treatment of COPD in 
Portugal over a 20 year time-horizon. MethodS: Using a stochastic individually 
based dynamic microsimulation model, health benefits were estimated as the dif-
ference in health outcomes between an intervention scenario and the status quo. 
The intervention considered is a screening program of smokers and ex-smokers 
aged 40 and over in primary healthcare settings, with selective referral to smoking 
cessation programs. In each scenario the model identifies: a) population with-
out COPD (NO-COPD); b) population with a COPD diagnosis (COPD-DIAG) and c) 
population with undiagnosed COPD (COPD-NODIAG). The calibration of the model 
assumes the mean forced expiratory volume in one second (FEV1) in individuals 
with COPD follows a normal distribution, as suggested by the literature. Following 
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, four 
severity stages were identified depending on the FEV1 value. Exacerbation fre-
quency and quality of life differ according to the stage of the individual. In each 
year, NO-COPD individuals have probabilities of transitioning to COPD according 
to sex, age and smoking habits; the FEV1 declines according to previous FEV1 level, 
smoking cessation and exacerbation episodes. Compared to COPD-NODIAG, the 
progression of the COPD-DIAG population is slower and quality of life higher due 
to medication and fewer exacerbation episodes per year. concLuSIonS: Early 
diagnosis and treatment of COPD may lead to substantial health gains. Modelling 
the disease evolution in order to assess the impact of future interventions is 
crucial to guide policy.
PRM245
HOw TO CAlCulATE vAluE Of iNfORMATiON iN SECONDS uSiNg ‘SAvi’, THE 
SHEffiElD ACCElERATED vAluE Of iNfORMATiON wEB APP
Strong M, Brennan A, Oakley J
University of Sheffield, Sheffield, UK
BAckground: Health economic models are used to estimate the expected costs 
and health outcomes of competing decision options. Model parameters are gener-
ally uncertain, and it is often useful to quantify the value of undertaking further 
data collection in order to reduce uncertainty. An upper bound on the value of 
resolving all uncertainty regarding an input parameter is quantified by its partial 
Expected Value of Perfect Information (EVPI). The value of a specific future study 
is quantified by its Expected Value of Sample Information (EVSI). PROBLEM: The 
standard approach to computing both partial EVPI and EVSI is via a nested two-
level Monte Carlo scheme that includes at each inner loop step both parameter 
sampling and model evaluation. This scheme can be prohibitively slow for complex 
models (eg. patient-level simulation models). Additional difficulties may occur in 
the calculation of EVSI if we have to resort to Markov-chain Monte Carlo (eg. using 
WinBUGS) to generate samples from the posterior distribution of the parameters 
given the simulated data for our proposed study. These difficulties have resulted in 
the restriction of Value of Information analyses to a small subset of health economic 
evaluations. SOLUTION: We have developed fast non-parametric regression based 
methods for computing both partial EVPI and EVSI. For partial EVPI we require only 
oBjectIveS: Remote monitoring (RM) is useful in chronic diseases, but evidence 
is scarce in home dialysis. Sharesource™, a two way connectivity platform with 
RM capabilities, should enable earlier intervention and healthcare savings. This 
abstract describes a simulation study designed to estimate the type and impor-
tance of the savings. MethodS: This study used an approach similar (although 
in a virtual environment) to that for diagnostic tests, i.e., additional information 
impact on treatment pathways. Automated peritoneal dialysis (APD) patient pro-
files (e.g., therapy non-compliance, fluid overload, etc.) were developed by a group 
of in-house nephrologists and nurses experienced in managing APD patients. Each 
patient profile was developed in 2 scenarios: “with RM” information (treatment 
data, blood pressure, weight) and “without RM”. Nephrologist (US= 4, Germany= 3, 
Italy= 2) experts in managing APD patients validated the “without RM” resources. 
The “with RM” resources were evaluated by 15 (US= 7, Germany= 4, Italy= 4) APD 
teams (1 nephrologist & 1 nurse). Resources were compared with t-tests. reSuLtS: 
Patient profile development required several rounds of individual and group 
reviews over a 6 month-period to ensure clarity of clinical event sequence and 
clinician management response. During the process, 8 profiles were abandoned, 
leaving 12 profiles for the simulation. Recruitment of experts and APD teams was 
moderately easy, the biggest hurdle was contract signature in some countries 
(e.g., Italy). Participants submitted responses, usually within two weeks. Overall, 
results indicate that RM could avoid 49-75 healthcare resources (4.1-6.2 per patient 
profile), including clinic calls/visits (48-72), but also hospitalizations (2), emer-
gency room visits (3.5-5) and transfer from APD to in-center hemodialysis (1-2.25). 
These patient profiles were perceived as representative of 17-37% of the APD 
patient population. concLuSIonS: This simulation was a rapid and affordable 
way of estimating the type and importance of potential reductions in healthcare 
resource consumption to be expected from RM in APD patients while waiting for 
real-world evidence.
PRM241
QuAliTy ASSESSMENT Of DiAgNOSTiC STuDiES: STuDy DESigNS lEADiNg 
TO HigH AND lOw RiSk Of BiAS
Pooley N, Fountain D, Cadwell K, Langham S
PHMR Ltd, London, UK
oBjectIveS: To investigate types of study design associated with classifications 
of either good or poor quality as defined by QUADAS-2, a new tool developed by 
Bristol University and used in decision-making evaluations for diagnostic technol-
ogy. MethodS: A pragmatic review of studies in Medline, Embase and the Cochrane 
Library was conducted to identify the widest possible variety of study designs used 
in the autoimmune disease therapeutic area. Using QUADAS-2, each study was 
assessed for a high, low or unclear risk of bias across four domains: patient selec-
tion, index test, reference standard and patient flow. reSuLtS: A number of study 
design features in the autoimmune disease area heavily influenced the risk of bias. 
Avoidance of a case-control design had the greatest impact overall. For example, 
case-control designs that enroll participants with known disease and include a 
control group without the condition may exaggerate diagnostic accuracy (patient 
selection domain), and they would make it more likely that biomarker assessment 
would be conducted with knowledge of the clinical diagnosis (index test domain). In 
contrast, a non-case-control design would mean that clinical assessment of the dis-
ease would be performed without knowledge of the results of the biomarker assess-
ment, leading to a low risk of bias (reference standard domain). concLuSIonS: 
Avoidance of a case-control study design had the biggest impact on QUADAS-2 
assessment of risk of bias in autoimmune disease diagnostic studies. Studies which 
exclude difficult-to-diagnose patients, such as those presenting with symptoms in a 
genuine diagnostic setting, may over-estimate test sensitivity. It is critical to adhere 
to design features leading to a low risk of bias because decision makers will review 
the quality of diagnostic accuracy studies based on QUADAS-2.
PRM242
PREDiCTivE ANAlySiS Of fACTORS iNfluENCiNg HEAlTH TECHNOlOgy 
ASSESSMENT RECOMMENDATiON: A liTERATuRE REviEw
Bossers N, Van Engen A, Heemstra L
Quintiles Advisory Services, Hoofddorp, The Netherlands
oBjectIveS: Health technology assessment (HTA) agencies apply different impor-
tance to different aspects of HTA submissions. It is therefore difficult to draw gen-
eralizable conclusions about the factors influencing subsequent recommendations. 
Previous studies have tried to identify country-specific factors, but there were differ-
ent techniques and parameters applied. The aim of this literature review is therefore 
to collate all parameters used in previous research in order to inform research into 
the predictive factors for HTA recommendations. MethodS: A systematic literature 
review was performed using PubMed. Examples of search terms used are “success”, 
“HTA” and “recommendation”. The time span was from 2004 to 2015. The studies 
differed in terms of methods used, parameters used and research questions. After 
the quality of the articles was assessed, the evidence provided in the literature was 
summarized and the findings were interpreted. The parameters analysed in the stud-
ies were compared taking into account country-specific requirements. reSuLtS: Out 
of sixteen articles identified, most studies evaluated NICE (six studies), followed by 
PBAC (four studies). The remaining studies evaluated different countries. A total of 
111 parameters were identified, which were grouped in three categories: clinical, 
economic and societal factors. The predictive clinical factors showed some regular-
ity explaining the HTA recommendation. Drug superiority, RCTs and the number of 
comparators were reoccurring explanatory variables. Economic factors showed most 
consistency among the studies. For NICE, cost-effectiveness proved to be an explana-
tory factor in all studies. Societal parameters were identified less often as explanatory 
factors, but included the burden of illness and company size. concLuSIonS: Many 
parameters have been used in previous research to explain the HTA decision, but 
there is no agreement yet on the driving parameters explaining the HTA-decision per 
agency. Hardly any study investigated an agency different than NICE or PBAC, which 
indicates that there is a knowledge gap for other agencies.
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target populations; 3) the need for fast, iterative assessments of technologies from 
development to implementation stages; 4) the need for ready available repositories 
of (country-specific) epidemiology and cost data; and 5) the need to extrapolate 
results over time and settings. To address these challenges, the Joint Research Center 
(JRC) of the European Commission has commissioned the construction of an online 
tool that allows stakeholders of the EIP on AHA to estimate the health economic 
impact of their interventions in real-time. At the core of this tool is a generic, highly 
adaptable Markov model with three mutually exclusive health states (‘baseline 
health’, ‘deteriorated health’ and ‘death’), combined with an extensive database of 
epidemiological, economic and effectiveness data. The tool assesses the impact of 
an innovation on resource use (both from a healthcare and societal perspective) and 
the Health Related Quality of Life of patients. We demonstrate the application and 
discuss the value of the tool using a case study from the EIP on AHA, on the develop-
ment of a falls prediction device. An early assessment (prior to clinical testing) was 
performed to estimate the possible impact of this intervention, considering various 
implementation scenarios. Finally, we will discuss the conceptual and practical nov-
elty as well as the (scientific) challenges of this approach for informing healthcare 
decisions regarding research funding, innovation development and implementation.
PRM249
CAPTuRiNg QuAliTy Of lifE (QOl) DATA iN RARE iNDiCATiONS: CASE STuDy 
iN RADiOiODiNE-REfRACTORy THyROiD CANCER (RR-DTC)
Hudgens S1, Pelletier C2, Forsythe A3, Taylor M4
1Clinical Outcomes Solutions, Tucson, AZ, USA, 2Eisai, Woodcliff Lake, NJ, USA, 3Eisai Inc., 
Woodcliff Lake, NJ, USA, 4Oregon Health and Science University, Portland, OR, USA
oBjectIveS: Capturing QOL information in orphan indications presents multiple 
barriers. Patient recruitment is challenging due to low incidence and severity 
of the condition. An additional consideration is the inability to make statistical 
inference due to low sample sizes. Outcomes research teams must consider novel 
methods for optimizing data collection and analysis within these populations. This 
case study evaluates the methods to address QOL data gaps in RR-DTC, a hard-to-
treat, rare cancer. MethodS: In a real-world observational study of patients with 
RR-DTC, a mixed-methods quantitative survey and qualitative data collection is 
being conducted to ascertain direct patient feedback through survey data collection 
and patient interviews. Sampling of patients is being done from the target popu-
lation in a real-world setting. This mixed-methods approach allows for an all-
encompassing understanding of the patient’s treatment experience and relevance 
of qualitative change to quantitative reporting within the clinical trial. Study docu-
ments capture symptoms and impact data cross-sectionally and longitudinally 
and to allow for the cross-linking of survey results to the clinical data. reSuLtS: 
Data will be presented on a sample of 120 patients: 50 currently undergoing sys-
temic therapy with sorafenib, 50 with lenvatinib, and 20 receiving no systemic 
therapy. QOL endpoints include the Functional Assessment of Cancer Therapy-
General (FACT-G), EQ-5D-5L, Symptoms & Toxicities experience, Impressions of 
Treatment Satisfaction, and Subject Preference. In addition, data from qualita-
tive interview of 40 patients will be presented to fully conceptualize quality of 
survival. The methods for patient recruitment and barriers to implementation 
will be presented as well as mixed methodology for interpreting quantitative 
survey data using supportive qualitative information. concLuSIonS: In absence 
of phase 3 QOL data in rare indications, a mixed-method approach utilizing real-
word observational study can yield important information that supports previ-
ously demonstrated survival benefit and help our understanding of treatment 
impact on quality of survival.
PRM250
filliNg THE gAP BETwEEN RiSk/BENEfiT ASSESSMENT fOR DRugS AND RiSk 
ASSESSMENT fOR CONSuMER gOODS
Hofmann-Xu L, Bonduelle D, Plantör S
IMS Health Germany, Munich, Germany
oBjectIveS: Drug authorization in Germany is regulated by the early benefit assess-
ment based on the risk-benefit ratio according to IQWiG General Methods. For con-
sumer goods, the Federal Institute for Risk Assessment (BfR) evaluates the risk by 
quantifying potential hazards and the exposure. Investigation regarding the gap 
between the assessments has rarely been done. This article aims to give a profound 
understanding of the concepts from IQWiG and BfR, and an initial recommendation 
to fill the gap. MethodS: The IQWiG General Methods and the BfR guidance for 
risk assessment are reviewed to compare their frameworks and evidence stand-
ards. Based on the results of the comparison, a product Xthat fits the gap between 
drugs and consumer goods is simulated and methods that fills the gap are recom-
mended. reSuLtS: Risk/Benefit assessment according to IQWiG is rigorously based 
on the Evidence Based Medicine (EBM) standards, while risk assessment accord-
ing to BfR has a clear focus on transparency of research. Risk/benefit according to 
IQWiG is assessed via patient-relevant endpoints, which is not applicable to the risk 
assessment of most consumer goods according to BfR. Recommendations for the 
simulated product Xinclude the adaption of the evidence standard, re-definition 
of risk and benefit and the application of mathematical models. concLuSIonS: 
Various gaps exist between risk/benefit assessment for drugs and risk assessment 
for consumer goods. As more and more emerging products are waiting for the mar-
ket launch, a new guidance that fills the gap and is applicable for these products 
would be highly necessary.
PRM251
THE POwER Of THE PATiENT vOiCE: fORMAliSiNg QuAliTATivE DATA iN THE 
DRug APPROvAl PROCESS
Willgoss TG, Meysner S, Kitchen H, Trigg A, Humphrey L
Abacus International, Manchester, UK
Pharmaceutical sponsors strive to capture the patient voice during drug develop-
ment. One emerging trend is the role that patient advocates can play in influencing 
regulatory decision making, often through powerful and emotive testimonials at 
the ‘probabilistic sensitivity analysis’ sample: a single set of samples from the model 
parameters, along with the corresponding modelled costs and health outcomes. 
The only extra requirement for EVSI is the ability to simulate study data. There is 
no need to re-run the model in either case. We have made available an easy-to-use, 
open access, web-based Value of Information calculator called ‘SAVI’ http://savi.shef.
ac.uk/SAVI. CONCLUSION: Value of Information measures can now be computed 
quickly for models of any complexity, and hence be made more widely available to 
modellers and decision makers.
PRM246
NORDiC lONgiTuDiNAl DATA fROM ElECTRONiC MEDiCAl RECORDS AND 
full POPulATiON NATiONAl REgiSTERS: uNiQuE OPPORTuNiTiES fOR NEw 
iNSigHTS iN BENEfiT Of DiABETES PATiENTS
Lindh A1, Persson F2, Sobocki P3, Bodegard J4, Lindarck N4
1Österåker Primary Care Center, Åkersberga, Sweden, 2Herlev University Hospital, Herlev, 
Sweden, 3Pygargus/IMS Health, Stockholm, Sweden, 4AstraZeneca Nordic, Södertälje, Sweden
oBjectIveS: Detailed data on type 2 diabetes mellitus (T2DM) patients and treat-
ment in clinical practice are scarce. The Nordic region offers unique opportunities 
for research on patient-level data from various complementary data sources, by 
availability of homogenous public healthcare systems with clinical information 
registered in electronic medical records (EMR) and mandatory national registers, and 
data linkage using the unique personal identification numbers for all inhabitants. 
This paper describes the implementation of a novel research methodology utilized 
in the Nordic countries to provide new T2DM insights based on a hybrid utilization of 
EMR data combined with national health registers, and supports the ongoing global 
DISCOVER program (NCT02322762). MethodS: This observational study collects 
both prospective health care data and retrospective longitudinal data. Patient-level 
information (e.g. demographics, diagnoses, clinical notes, laboratory results, health 
care contacts and referrals) of the enrolled T2DM patients will be extracted from EMR 
at each study site. To facilitate clinical data completeness, specific variables will be 
collected by electronic case report forms. In addition, the national full population 
registers (patient-, cause of death- and prescribed drug registers) provide longitudi-
nal data for the enrolled T2DM patients, the complete study site T2DM cohorts, and 
the nationwide full T2DM population. reSuLtS: This approach, bridging data from 
the enrolled T2DM patients, the complete cohort of T2DM patients at the study sites, 
and the nationwide full population, generates extended observational data with 
high internal and external validity from approximately 1 million T2DM patients. 
Iterative data collection spanning several years (2015 – 2018), thus potentiating 
interim analyses, will provide contemporary insights of T2DM disease progression 
and treatment development. concLuSIonS: This novel methodology presents a 
new era for observational research, providing efficient ways of generating com-
prehensive data with high completeness and minimal interference with ordinary 
clinical practice. This is highly relevant for diabetes and other chronic diseases.
PRM247
NEw STANDARDS TO DERivE PREfERENCE-BASED HRQOl vAluES
Krabbe PF
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
BAckground: What distinguishes informative health outcomes from all other 
measures of health is whether these are based on the perception and preferences 
of patients. New HRQoL preference-based measurement methods that use the 
patient’s own evaluations as the point of reference (patient-centered) seems essen-
tial. Existing problems All existing generic preference-based HRQoL instruments 
(e.g. EQ-5D, HUI, SF-6D) use a small, fixed set of health attributes, forming descrip-
tions of health states that are valued by samples of the general population. When 
developing those instruments, patients’ opinions were not actively incorporated in 
the choice of attributes, nor have patients’ preferences been considered in assessing 
weights to the attributes. Compelling arguments against the currently dominant val-
uation technique, the time trade-off, have been raised by several authors. For these 
reasons, the existing instruments seem to lack credibility. An improved approach We 
developed a completely novel preference-based HRQoL measurement instrument 
that combines the strength of two existing measurement models: discrete choice 
modeling and Rasch item response theory. It is referred to as the multi-attribute 
preference response (MAPR) model. The response mechanism of the MAPR model 
is insensitive to various biases (e.g., adaptation, time preference, indifference pro-
cedure). Moreover, this is the first generic HRQoL preference-based model that is 
fully based on the perception and reporting from patients. The response task for the 
patient is to judge whether a hypothetical health-state description is considered to 
be worse or better than the health condition of the patient himself. Apart from being 
grounded on measurement theory, the tasks are easy and attractive to perform in 
a self-completion setting. Conclusion After years of dominance of ad hoc methods 
to derive values for patients’ health conditions, we present an informative HRQoL 
measurement model that overcomes credibility problems facing the conventional 
instruments.
PRM248
EARly HEAlTH ECONOMiC ASSESSMENT iN iNNOvATiON PARTNERSHiPS: 
lESSONS fROM THE EuROPEAN iNNOvATiON PARTNERSHiP ON ACTivE AND 
HEAlTHy AgEiNg
de Graaf G1, Steuten L2, Pecchia L3, Boehler C4
1Panaxea BV, Enschede, The Netherlands, 2University of Washington and Panaxea bv, Seattle, 
WA, USA, 3University of Warwick, Coventry, UK, 4European Commission, Joint Research Centre, 
Sevilla, Spain
On European and national levels substantial investments are done in partnerships 
that aim to stimulate the development and implementation of healthcare innova-
tions. One such partnership is the European Innovation Partnership on Active and 
Healthy Ageing (EIP on AHA). Monitoring and assessing the societal, healthcare 
and patient impact of such large innovation partnerships is challenging for many 
reasons, including 1) the wide range of interventions developed; 2) the variety in 
